ArticleNature communications2023
FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Fgl2-knockout tumor cells serve as a vaccine inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges.Cancer letters · 2026Article
- Tissue-Resident Memory T Cells: Pioneering New Avenues in Cancer Immunotherapy.Cancer medicine · 2025Review
- Activation and Long-Term Maintenance of Adaptive Immunity in the Central Nervous System: A Double-Edged Sword?CNS neuroscience & therapeutics · 2025Review
- Preliminary exploration of the role of fibrinogen-like protein 2 in neuroblastoma.Scientific reports · 2025Article
- Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models.Journal for immunotherapy of cancer · 2025Article
- Palmitoylation modulates antitumor immunity.Molecular biology reports · 2025Review
- FGL2-induced metabolic dysregulation in enteric neural crest cells provides insight into Hirschsprung disease pathogenesis.iScience · 2025Article
- CD103Clinical and translational medicine · 2025Article
- Role of lysine acetylation-related genes in the diagnosis and prognosis of glioma.Scientific reports · 2025Article
- Multifaceted functions of tissue-resident memory T cells in tumorigenesis and cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2025Review
- Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma.JCI insight · 2025Article
- Keeping it local: how CD8 TRMs regulate viral and cancer immunity.Frontiers in immunology · 2025Review
- Persistent tailoring of MSC activation through genetic priming.Molecular therapy. Methods & clinical development · 2024Article
- Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression.Acta pharmaceutica Sinica. B · 2024Review
- Identification of two key biomarkers CD93 and FGL2 associated with survival of acute myeloid leukaemia by weighted gene co-expression network analysis.Journal of cellular and molecular medicine · 2024Article
- CD8Nature communications · 2024Article
- Prognostic significance and gene co-expression network of CD16A and FGL2 in gliomas.Frontiers in oncology · 2024Article
- The Role of CXCR3 in Nervous System-Related Diseases.Mediators of inflammation · 2024Review
- Aspirin and immunotherapy: a Faustian bargain?The Journal of clinical investigation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Qingnan ZhaoDepartment of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200020, China.ORCID 0000-0001-9389-8566
Jiemiao HuDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-5142-0641
Lingyuan KongDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Shan JiangUaub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, 77030, USA.
Xiangjun TianDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-5398-0802
Rintaro HashizumeDepartment of Neurological Surgery, Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Zhiliang JiaDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Natalie Wall FowlkesDepartment of Veterinary Medicine & Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-7711-6031
Jun YanBeijing Institute of Brain Disorders, Capital Medical University, Beijing, 100069, China.
Xueqing XiaDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Sofia F YiDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Long Hoang DaoDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
David MasopustDepartment of Microbiology, Center for Immunology, University of Minnesota, Minneapolis, MN, 55455, USA.ORCID 0000-0002-9440-3884
Amy B HeimbergerDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-9970-8695
Shulin LiDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. Sli4@mdanderson.org.ORCID 0000-0001-5657-4183
The University of Texas MD Anderson Cancer Center · USCapital Medical University · CNInstitute on Aging · USNorthwestern University · USUniversity of Minnesota · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MFgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapseR01NS122857 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIMBERGER, AMY BETH, LI, SHULIN · 2021 to 2025
$2.9MFgl-2 targeted therapy for reversing multi-modality immune suppressionR01CA203493 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIMBERGER, AMY BETH, LI, SHULIN · 2016 to 2020
$1.8MTumor-Targeted Chemo-Immunotherapy for Osteosarcoma MetastasisR01CA200574 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LI, SHULIN, ZHANG, LIANGFANG · 2016 to 2020
$1.8MNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA200574NCI NIH HHS R01 CA203493NINDS NIH HHS R01 NS122857
Abstract
Although tissue-resident memory T (T
Indexed as
CD8-Positive T-LymphocytesGlioblastomaAnimalsBrainFibrinogenImmunologic MemoryMemory T CellsMiceNeoplasm Recurrence, LocalT-LymphocytesFgl2 protein, mouseFibrinogen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.